Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors

BACKGROUND: Atypical teratoid/thabdoid tumor (AT/RT) remains a difficult-to-treat tumor with a 5-year overall survival rate of 15%–45%. Proteasome inhibition has recently been opened as an avenue for cancer treatment with the FDA approval of bortezomib (BTZ) in 2003 and carfilzomib (CFZ) in 2012. Th...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neurooncol Adv
Main Authors: Morin, Andrew, Soane, Caroline, Pierce, Angela, Sanford, Bridget, Jones, Kenneth L, Crespo, Michele, Zahedi, Shadi, Vibhakar, Rajeev, Mulcahy Levy, Jean M
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Basic and Translational Investigations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7236404/
https://ncbi.nlm.nih.gov/pubmed/32642704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa051
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares